1 / 18

How can the Pharma Industry assist the NHS in constrained times? Can Pharma help with QIPP?

How can the Pharma Industry assist the NHS in constrained times? Can Pharma help with QIPP? PDIG meeting, 10 June 2010 Alison Clough Commercial & Communications Director, Association of the British Pharmaceutical Industry. The environment is getting tougher. Ageing demographic.

makoto
Download Presentation

How can the Pharma Industry assist the NHS in constrained times? Can Pharma help with QIPP?

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. How can the Pharma Industry assist the NHS in constrained times? Can Pharma help with QIPP? PDIG meeting, 10 June 2010Alison Clough Commercial & Communications Director, Association of the British Pharmaceutical Industry

  2. The environment is getting tougher Ageing demographic Increasing demand on healthcare resources Economic slowdown Acceleration of technical advancement

  3. Win- win-win Partners in Improving Care and Healthcare Delivery

  4. November 2009 Through the continued process of innovation in the UK, further benefits can Innovation fuels better patient outcomes • 1 in 5 of the leading medicines used around the world were developed by a UK Company • Increase in life expectancy over time Prescription for innovation (ABPI 2009); WHO (2006)

  5. Coronary heart disease OHE calculation based on WHO Mortality Database (WHO), Mortality Statistics Series DH2 (ONS), Mortality Statistics Deaths Registered DR_06 (ONS), Vital Events Reference Tables (General Register Office of Scotland), Demographic Statistics (Northern Ireland Statistics and Research Agency), Population Estimates and Projections (ONS).

  6. Mortality rates from disease remain high - there remains scope for further improvement in public health Heart and circulatory disorders –leading cause of death in England in 2007, resulting in 158 500 deaths (34% of all deaths) Cancer responsible for 23% of all deaths 34% 23% Atlas of Risk (NHS 2009) Slide reproduced courtesy of Pfizer

  7. Medicines Life Cycle in UK ...delivering efficiencies but out of balance ...? UK has slow & low use of innovative medicines The UK has amongst the lowest market share of new medicines across Europe Encourage Innovation Source: Compendium of Health Statistics 2009 (OHE), updated Hospital prescribing data (IC) PPA and PCA data. Market Statistics IMS World Review, OECD GDP data. PPRS reports to Parliament 6th and 10th IMS world review EGA National Association 2007.

  8. Comparatively, UK has low new product uptake Source: IMS world review

  9. Medicines Life Cycle in UK ...delivering efficiencies but out of balance ...? UK prices are amongst the lowest in Europe UK has slow & low use of innovative medicines 3 price cuts since 2005 The UK has amongst the lowest market share of new medicines across Europe Maximise value for patient, NHS & Industry Encourage Innovation Source: Compendium of Health Statistics 2009 (OHE), updated Hospital prescribing data (IC) PPA and PCA data. Market Statistics IMS World Review, OECD GDP data. PPRS reports to Parliament 6th and 10th IMS world review EGA National Association 2007.

  10. UK prices lowest in official PPRS Report to Parliament-December 2009 Table: price index for top 150 UK branded medicines (UK = 100) Bilateral comparisons of ex-manufacturer prices (sources PPRS reports to Parliament 6th and 10th)

  11. Medicines Life Cycle in UK ...delivering efficiencies but out of balance ...? UK prices are amongst the lowest in Europe UK has very efficient use of generics UK has slow & low use of innovative medicines • 3 price cuts since 2005 • 83% generic prescribing • 65% by volume is generics • Average price of generics amongst lowest in Europe The UK has amongst the lowest market share of new medicines across Europe Maximise value for patient, NHS & Industry Encourage Innovation Efficiency Source: Compendium of Health Statistics 2009 (OHE), updated Hospital prescribing data (IC) PPA and PCA data. Market Statistics IMS World Review, OECD GDP data. PPRS reports to Parliament 6th and 10th IMS world review EGA National Association 2007.

  12. The UK is amongst the EU markets with largest penetration of generics, with ~65% of volume Generics market share in Europe (2006) Generics share of volumes (%) Generics share of value (%) 2009 UK generic prescribing rate =83% • Source: EGA National Association 2007

  13. Medicines Life Cycle in UK ...delivering efficiencies but out of balance ...? UK prices are amongst the lowest in Europe UK has very efficient use of generics UK has slow & low use of innovative medicines • price cuts since 2005 • 83% generic prescribing • 65% by volume is generics • Average price of generics amongst lowest in Europe The UK has amongst the lowest market share of new medicines across Europe Maximise value for patient, NHS & Industry Encourage Innovation Efficiency Only 1% GDP is spent on medicines in UK cf EU average 1.5%, Fr 2%, Greece 2.3% Source: Compendium of Health Statistics 2009 (OHE), updated Hospital prescribing data (IC) PPA and PCA data. Market Statistics IMS World Review, OECD GDP data. PPRS reports to Parliament 6th and 10th IMS world review EGA National Association 2007.

  14. Total Medicines Bill as a % of NHS spend has been in sustained decline since 2004 NHS spend and Medicines Bill as a percentage of the NHS costs 1998-2008 % Annual Spend (£billion) Source: Compendium of Health Statistics 2009 (OHE), updated Hospital prescribing data (IC) PPA and PCA data

  15. Economic picture • The medicines bill is already delivering efficiencies and is under control. • Important to meet NHS / health needs as well as economic /industrial policy. • Pharma is one of the key industries underpinning economic recovery. Driving health & economic benefit for the UK

  16. Opportunities for industry participation in QIPP • Joint working - implement national strategies for long term conditions or tackle local priorities • Many examples contained within the ABPI/DH ‘Moving Beyond Sponsorship’ Toolkit. • Support for the redesign of care pathways - ensure the appropriate use of innovative new medicines. • Management support to review processes & support change programmes.

  17. Happy Hearts Project Aim- to find and treat ‘hard to reach’ patients with multiple CVD risk factors and improve patient care and services in Nottingham. • Nottingham City PCT and six companies with ABPI • Primary care based CVD risk identification and management • Nottingham mortality rates significantly higher than the national average. • Targeted at 13 GP practices in most deprived areas Identified 1352 patients (66%) with a risk level of >20%. Patients were given support to manage and reduce that risk including appropriate medication.

  18. Partners in Improving Care and Healthcare Delivery Driving Health and Economic Benefit for the UK

More Related